Specifically, immune checkpoint inhibitors (ICIs), targeting the programmed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) axis, have been approved for first- or second-line treatments of NSCLC, regardless of the patient’s history or driver mutational status (2, 3). Here, CD274 is linked to non-small cell lung carcinoma.